CalciMedica Inc. (NASDAQ:CALC) Stock Short Interest Jumps 178.0%

CalciMedica Inc. (NASDAQ:CALC) was the target of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 171,388 shares, a growth of 178.0% from the October 15th total of 61,641 shares. Currently, 3.5% of the shares of the company are short sold. Based on an average trading volume of 96,501 shares, the days-to-cover ratio is presently 1.8 days.

Institutional Trading of CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Renaissance Technologies LLC increased its stake in CalciMedica Inc. (NASDAQ:CALC) by 45.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 128,075 shares of the company’s stock after acquiring an additional 39,775 shares during the period. Renaissance Technologies LLC owned approximately 0.81% of CalciMedica worth $69,000 as of its most recent SEC filing.

Wall Street Analyst Weigh In

CALC has been the subject of several analyst reports. UBS Group restated a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Guggenheim assumed coverage on CalciMedica in a report on Thursday, August 20th. They set a “buy” rating for the company. Weiss Ratings upgraded CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Finally, Wall Street Zen downgraded CalciMedica from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, CalciMedica currently has an average rating of “Hold” and an average target price of $50.00.

CalciMedica Stock Performance

CALC opened at $1.22 on Friday. The stock has a market capitalization of $8.42 million, a price-to-earnings ratio of -0.27 and a beta of 0.84. The company has a fifty day moving average of $1.56 and a 200 day moving average of $3.12. CalciMedica has a fifty-two week low of $1.00 and a fifty-two week high of $36.00. The company has a debt-to-equity ratio of 1.63, a quick ratio of 5.58 and a current ratio of 4.96.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($1.27) by $1.03. As a group, sell-side analysts forecast that CalciMedica will post -1.93 earnings per share for the current fiscal year.

CalciMedica Company Profile

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses. CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.